1A01050
USP
6-Methyl-4-Phenylchromanol
Pharmaceutical Analytical Impurity (PAI)
Sinónimos:
(6-Methyl-4-phenylchroman-2-ol)
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Fórmula empírica (notación de Hill):
C16H16O2
Número de CAS:
Peso molecular:
240.30
Código UNSPSC:
41116100
NACRES:
NA.24
Productos recomendados
grado
pharmaceutical analytical impurity (PAI)
Agency
USP
fabricante / nombre comercial
USP
aplicaciones
pharmaceutical
formato
neat
temp. de almacenamiento
2-8°C
Descripción general
[6-Methyl-4-phenylchromanol (25 mg) (6-Methyl-4-phenylchroman-2-ol)] - CAS [209747-04-6] (usp.org)6-Methyl-4-Phenylchromanol is a USP Pharmaceutical Analytical Impurity (PAI).
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Tolterodine tartrate.
Therapeutic Area: Renal.
For more information about this PAI, visit here.
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Tolterodine tartrate.
Therapeutic Area: Renal.
For more information about this PAI, visit here.
Aplicación
6-Methyl-4-Phenylchromanol (USP PAI) is intendedfor use in analytical testing to detect, identify, and measure pharmaceuticalimpurities.
Características y beneficios
USP PAI advance your early analytical R&D and process development. PAI can be used in the following applications:
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico